LAK细胞回输对肿瘤患者血清铜锌影响的初步观察

本文应用原子吸收分光光度法对９例肿瘤患者ＬＡＫ细胞回输前后血清铜锌含量进行了测定。结果表明，回输后血清钢下降，锌升高，Ｃｕ／Ｚｎ比值降低，与对照组比有差异（Ｐ＜０．０１），提示ＬＡＫ细胞回输有提高血清锌水平作用，这可能与锌参与ＬＡＫ细胞杀肿瘤机制有关。Ｐ＜０．０５结果ＬＡＫ细胞回输后血清Ｚｎ、Ｃｕ及Ｃｕ／Ｚｎ比值均与治疗前存在差异（Ｐ＜０．０１），表现为ＣＵ水平下降，Ｚｎ水平升高，Ｃｕ／Ｚｎ比值降低，接近正常对照组水平（Ｐ＞０．０５）。见附表。讨论研究业已表明，肿瘤患者具有Ｃｕ高Ｚｎ低Ｃｕ／Ｚｎ比值升高的表现。Ｚｎ缺乏将在多方面影响人体免疫功能的正常发挥，导致细胞毒性Ｔ细胞功能下降。因此，肿瘤患者缺Ｚｎ将促使进一步向恶性化发展。加入Ｚｎ有可能增强细胞毒性Ｔ细胞功能，促进淋巴细胞转化，增加免疫调节功能，从而延缓肿瘤进展。本文观察到的结果表明，ＬＡＫ细胞回输可影响患者血清Ｃｕ、Ｚｎ水平，且以Ｚｎ增高，Ｃｕ／Ｚｎ比值下降为特征。因此，ＬＡＫ细胞治疗肿瘤患者过程中血清Ｃｕ、Ｚｎ的变化，可能与ＬＡＫ细胞治疗肿瘤机制有关。同时也为临床肿瘤治疗过程中补充Ｚｎ制剂提供了一定的佐证。参考文献     

子宫颈鳞癌患者放疗前后血清铜、锌的变化

目的检测子宫颈癌患者放疗前后血清铜、锌的变化，检测子宫颈癌患者与正常人血清铜、锌水平的比较。材料与方法采用三电极直流等离子原子发射光电直读光谱仪法检测。结果子宫颈鳞癌患者血清铜（ＳＣｕ）、铜锌比值（Ｃｕ／Ｚｎ）显著高于正常对照组（Ｐ＜０．００１），Ⅲ期患者又显著高于Ⅱ期患者（Ｐ＜０．００１）；放疗后癌灶完全消退者（ＣＤ）ＳＣｕ、Ｃｕ／Ｚｎ明显下降（Ｐ＜０．０１）；部分消退者（ＰＤ）二值仍处于高水平。结论：ＳＣｕ和Ｃｕ／Ｚｎ可以检测放疗疗效，估计预后，有一定临床意义。     

头颈部肿瘤放疗后血清Cu,Zu检测的临床意义

对６０例头颈部肿瘤放疗前后患者的血清Ｃｕ，Ｚｎ，Ｃｕ／Ｚｎ比值进行了检测，结果显示：放疗前血清Ｃｕ明显高于正常对照组和放疗后（Ｐ〈０．０５）；血清Ｚｎ地正常对照组和放疗后（Ｐ〈０．０５），放疗后组血清Ｃｕ／Ｚｎ比值明显于高于正常对照和放疗后（Ｐ〈０．０５），放疗后血清Ｃｕ，Ｚｎ，Ｃｕ／Ｚｎ比值与正常对照组无明差异，放疗后复发组血清Ｃｕ明显高于放疗后无复发组（Ｐ〈０．０１）；血清Ｃｕ／Ｚｎ比值明显高     

急性白血病患者血清中锰镍镉铜锌及全血中铜锌锰的研究

用原子吸收光谱法测定３４例急性白血病患者和４０例正常人血清中锰（Ｍｎ）、镍（Ｎｉ）、铜（ｃｕ）、锌（ｚｎ）、镉（Ｃｄ）及全血中Ｃｕ、Ｚｎ和Ｍｎ的含量，观察到急性白血病的ＡＬＬ组和ＡＮＬＬ组患者血清、全血Ｃｕ的含量、铜锌比值（Ｃｕ／Ｚｎ）显著高于正常人（Ｐ＜０．００１）；血清、全血Ｚｎ、血清Ｍｎ含量均显著低于对照组（Ｐ＜０．００１，Ｐ＜０．０５）；血清Ｎｉ含量升高仅见于ＡＬＬ组（Ｐ＜０．０１）．血清铜含量升高与合髓白血病细胞增殖有关。     

康莱特注射液对胃肠道恶性肿瘤患者免疫功能的影响

目的　探讨康莱特注射液对胃肠道恶性肿瘤患者免疫功能的影响。方法　对 ５０ 例胃肠道恶性肿瘤病人分别于术前、术后３ 周抽取外周血对 Ｔ 淋巴细胞亚群和血清 Ｓ Ｉ Ｌ２ Ｒ 水平表达进行检测,随机将 ５０ 例患者分为单纯手术组（２８ 例）和应用康莱特组（２２ 组）,并与 ４２ 例健康人对照比较。结果　与正常对照组相比胃肠道恶性肿瘤病人 Ｔ 淋巴细胞亚群中 Ｃ Ｄ３＋ 细胞、 Ｃ Ｄ４＋ 细胞减少, Ｃ Ｄ４＋ ／ Ｃ Ｄ８＋ 细胞比值下降（ Ｐ＜ ０．０５）,血清 Ｓ Ｉ Ｌ２ Ｒ 水平升高（ Ｐ＜ ０．０１）;手术切除肿瘤后, Ｃ Ｄ３＋ 细胞、 Ｃ Ｄ４＋ 细胞增加, Ｃ Ｄ４＋ ／ Ｃ Ｄ８＋ 细胞比值升高（ Ｐ＜ ０．０５）,血清 Ｓ Ｉ Ｌ２ Ｒ 水平降低（ Ｐ＜ ０．０１）。使用康莱特注射液后, Ｃ Ｄ３＋ 细胞、 Ｃ Ｄ４＋ 细胞明显增加, Ｃ Ｄ４＋ ／ Ｃ Ｄ８＋ 细胞比值增高（ Ｐ＜ ０．０５）, Ｓ Ｉ Ｌ２ Ｒ水平下降（ Ｐ＜ ０．０５）。结论　康莱特注射液能明显提高胃肠道恶性肿瘤患者的免疫功能。     

肿瘤患者血清铜锌及其比值测定的意义

目的探讨恶性肿瘤患者血清铜、锌水平和铜／锌比值的应用价值。方法 本文采用美国ＰＥ公司３０３０型原子吸收分光光度计,对１２３０例恶性肿瘤患者,２１０例良性疾病患者和１００例健康成人,进行血清铜、锌水平和铜／锌比值的测定。结果 恶性肿瘤口才的血清铜水平和铜、锌比值明显高于良性疾病组和健康对照组,而血清锌低于健康对照组,有统计学意义。血清铜／锌比值对卵巢癌诊断阳性率为８１．４８％;宫颈癌为７１．０％;肝     

生长抑素SMS201—995对小鼠结肠癌肝转移瘤的实验研究

本研究观察生长抑素衍生素ＳＭＳ２０１－９９５对ＢＡＬＢ／ｃ小鼠结肠腺癌肝转移瘤细胞周期的影响，检测血清ＣＥＡ水平的变化，并观察小鼠生存期的改变。采用流式细胞术。与对照组相比，ＳＭＳ２０１－９９５治疗组的瘤细胞增殖指数和Ｓ期细胞百分比明显降低（Ｐ〈０．０１）而Ｇ０／Ｇ１期细胞百分比则明显增加（Ｐ〈０．０１）。治疗组血清ＣＥＡ水平较对照组显著降低（Ｐ〈０．０５），生存期明显延长。治疗组细胞增殖指数，Ｓ     

单香菇多糖注射液对妊娠滋养细胞肿瘤化疗疗效和免疫功能的 …

目的 研究单香菇多糖注射液与化疗合用对妊娠滋养细胞肿瘤（ＧＴＮ）的疗效和免疫指标的影响。方法 随机将３６例ＧＴＮ分成两组，分别为化疗组（Ａ）和化疗＋单香菇多糖组（Ｂ）各１８例，观察化疗疗效，毒副反应和外周血Ｔ４／Ｔ８细胞比值和ＮＫ细胞活性的变化。结果 两组临床特征，化疗疗效和Ｔ４／Ｔ８比值差异无显著性（Ｐ〉０．０５），但Ｂ组治疗后ＮＫ细胞活性增高显著高于Ａ组（Ｐ〈０．０１），未观察到严重的毒副作用     

胃癌患者血清sIL－2R测定的临床价值

应用双抗加心法对７８例胃癌患者血清可溶性白介素２受体（ｓＩＬ－２Ｒ）进行临床研究。结果发现：胃癌患者ｓＩＬ－２Ｒ水平明显高于胃良性疾病患者和正常人（Ｐ＜０．０１）；Ⅲ、Ⅳ期高于Ⅰ、Ⅱ期（Ｐ＜０．０５）；手术切除后（根治或姑息）ｓＩＬ－２Ｒ显著下降（Ｐ＜０．０１）；手术后复发和转移患者血清ｓＩＬ－２Ｒ升高（Ｐ＜０．０１）；如果患者血清ｓＩＬ－２Ｒ高于１０００Ｕ／ｍｌ，生存期短。提示胃癌患者ｓＩＬ－２Ｒ水平高低与肿瘤分期、手术方式、复发转移和预后有关，监测胃癌患者血清ｓＩＬ－２Ｒ水平对临床病情和预后有重大意义。     

胃癌患者血清sIL—2R测定的临床价值

应用双抗加心法对７８例胃癌患者血清可溶性白介素２受体（ｓＩＬ－２Ｒ）进行临床研究。结果发现：胃癌患者ｓＩＬ－２Ｒ水平明显高于胃良性疾病患者和正常人（Ｐ〈０．０１）；Ⅲ、Ⅳ期高于Ｉ、Ⅱ期（Ｐ〈０．０５）；手术切除后（根治或姑息）ｓＩＬ－２Ｒ显著下降（Ｐ〈０．０１）；手术后复发和转移患者血清ｓＩＬ－２Ｒ升高（Ｐ〈０．０１）；如果患者血清ｓＩＬ－２Ｒ高于１０００Ｕ／ｍｌ，生存期短。提示胃癌患者ｓＩＬ－２     

消化道肿瘤患者血清锌,铜水平及铜／锌比值的临床观察

本文应用ICP-光谱法对50例消化道肿瘤病人的血清锌、铜及铜/锌比值作了对照性观察、结果表明肿瘤病人的血清锌低于对照组、血清钢及铜/锌比值高于对照、差异非常显著(P<0.001、P<0.005)。有远位转移组与无转移组相比;静脉营养组与进食组相比,血清锌、铜及铜/锌比值差异不显著(P>0.05～0.10)。因此,认为血清锌低、铜及铜/锌比值增高是本组肿瘤病人的特征,可作为肿瘤监测的一个指标,但是,不能作为判断预后的依据。     

恶性淋巴瘤患者血清锌,铜和铜锌比值测定及其临床意义

本文测定６３例恶性淋巴瘤患者的血清Ｃｕ、Ｚｎ，并以８６例正常人作对照。用国产ＧＧＸ－２型原子吸收分光光度计测定，同时平行测定牛血清标准参考物质。测定结果经统计学处理，恶性淋巴瘤患者ＳＣｕ升高，ＳＺｎ显著低于正常对照组；与对照组比较，Ｃｕ／Ｚｎ比值明显升高（Ｐ＜０．０１）。ＮＨＤ弥漫型的Ｃｕ／Ｚｎ比值明显高于结节型（Ｐ＜０．０１）。作者认为恶性淋巴瘤的发展程度与Ｃｎ、Ｚｎ的浓度有关，与Ｃｕ／Ｚｎ比值的升高密切相关。比值升高提示病情发展。所以，Ｃｎ／Ｚｎ比值对恶性淋巴瘤的疗效和予后有一定的参考价值。     

Diagnostic value of serum copper/zinc ratio in gynecologic tumors

Serum copper/zinc levels were determined in 39 patients with gynecologic tumors and 20 normal individuals. Of these 39 patients, twenty-two had primary malignant tumors and seventeen had benign growths. All the patients were divided into two groups: treated and untreated. The serum Cu/Zn ratio in the untreated benign tumors was significantly higher than of the normal controls (P less than 0.05). The ratio was much higher in the untreated Stage II-IV malignant tumors than that of the benign group (P less than 0.01). The measurement of serum Cu/Zn ratio is also helpful in observing the clinical course of the disease.     

Quantitative analysis of copper,zinc and copper/zinc ratio in selected human brain tumors

Summary Serum copper and zinc concentrations and copper/zinc ratios have been shown to be increased in several types of human malignancies, including human brain tumors. In this study, copper and zinc levels and copper/zinc ratios were determined by atomic absorption analysis in tissue and serum from 29 primary and metastatic brain tumor patients. Metastatic carcinomas and malignant gliomas revealed significantly higher tissue copper concentrations than control tissues and meningiomas. Malignant gliomas demonstrated significantly higher tissue copper/zinc ratios. Both serum copper and copper/zinc ratio were significantly higher in the metastatic carcinoma group than control; however, serum copper levels in malignant glioma patients were not significantly different from control tissues. There were no differences both in the serum and the tissue concentrations of these trace elements in meningiomas and controls. These data suggested that copper, an important angiogenic factors, is accumulated within the malignant tissues of metastatic carcinoma and malignant glioma, but not meningiomas. These findings may have implications regarding angiogenesis in these tumors.     

Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort

Copper and zinc are essential micronutrients, whose imbalance may be involved in the development and progression of cancer. However, the role of copper and/or zinc imbalance in the prognosis of hepatocellular carcinoma (HCC) is currently unclear. Our objective was to investigate the association between serum levels of copper, zinc and their ratio (copper/zinc) at diagnosis with HCC survival. We included 989 patients with incident HCC in this prospective cohort study, who were enrolled in the Guangdong Liver Cancer Cohort (GLCC) study within 30 days of diagnosis between September 2013 and February 2017. Serum copper and zinc were measured using inductively coupled plasma mass spectrometry. Primary outcomes were liver cancer-specific survival (LCSS) and overall survival (OS). Cox proportional hazards models were used to calculate the multivariable hazard ratios (HRs) and 95% confidence interval (CI). Higher serum copper levels were strongly associated with worse LCSS (Q4 vs. Q1: HR = 1.87, 95% CI: 1.22–2.86; p < 0.01 for trend) and OS (Q4 vs. Q1: HR = 2.06, 95% CI: 1.36–3.11; p < 0.01 for trend). The calculated copper/zinc ratio was positively associated with LCSS (Q4 vs. Q1: HR = 1.31, 95% CI: 0.89–1.92; P = 0.04 for trend) and OS (Q4 vs. Q1: HR = 1.43, 95% CI: 0.99–2.08; P = 0.01 for trend). No overall associations were observed between serum zinc levels and LCSS or OS in the entire cohort. The results suggest that higher serum copper and copper in relation to zinc levels (i.e., higher copper/zinc ratio) may be associated with worse HCC survival, but serum zinc levels may be not associated with HCC survival.     

消化道良,恶性疾病的12种微量元素的测定与临床意义

本文测定174例胃肠道疾病,40例原发性肝癌及85例正常人血清Cu、Zn、Ca、Mg、Fe、Sr、Mn、Mo、Cr、Ti、Ni、Se等12种微量元素。结果表明:血清铜升高、锌降低,Cu/Zn比值升高最明显为原发性肝癌,其次为胃肠癌,再次为胃肠息肉,最后为慢性腹泻。慢性腹泻与正常比仅锌下降,钙与锌在各组改变与锌相似。胃肠癌转移组与正常组比,术前组、术后组与正常组之间其Cu/Zn比值升高,且均有统计学意义(P<0.05)。胃肠癌组与息肉组比较,血清钙显著降低(P<0.001),铁无差异;而胃肠癌组与慢性腹泻组比,血清铁降低显著而钙无差异。胃肠癌中65例腺癌病理分化与微量元素无明显关系。由此表明微量元素改变对鉴别消化道良、恶性疾病和临床观察有一定帮助。     

Serum and tissue trace elements in colorectal cancer

Serum copper, zinc, and Cu/Zn ratio were measured using atomic absorption spectrophotometry in 30 patients with colorectal cancer and compared with 30 healthy control subjects. In the patients with colorectal cancer, the tissue copper and zinc levels were also measured in paired histologically normal and malignant colorectal tissue samples obtained at surgery. The mean serum copper levels were higher in patients with colorectal cancer (165.99 vs. 98.84 μg/dl) (P < 0.001). The mean serum zinc levels were lowered only in advanced (Dukes stages C and D) colorectal cancer compared to controls (89.94 vs. 115.08 μ/dl) (P < 0.001). However, the Cu/Zn ratio progressively increased with the advancing stage of malignancy (1.86 vs. 0.86) (P < 0.001). The cancerous colorectal tissue showed a higher concentration of both copper (2.78 vs. 1.79 μg/g) (P < 0.001) and zinc (27.16 vs. 18.98 μg/g) (P < 0.01) compared to non-cancerous colorectal tissue. The exact mechanism responsible for the alterations in trace element levels in patients with colorectal cancer is largely unclear and requires further evaluation. However, the serum copper level and the Cu/Zn ratio are of value in estimating the extent of the carcinoma as well as in determining the prognosis of these patients. © 1993 Wiley-Liss, Inc.     

Serum trace elements and Cu/Zn ratio in breast cancer patients

Serum copper, zinc, and the Cu/Zn ratio were measured in 55 patients with breast disease (20 with benign breast diseases and 35 patients with breast cancer) and 30 controls. The mean serum copper levels were higher in breast cancer than in benign breast diseases (167.3 micrograms/dl vs. 117.6 micrograms/dl) (P less than 0.001) and controls (167.3 micrograms/dl vs. 98.8 micrograms/dl) (P less than 0.001). Patients with advanced breast cancer had higher serum copper levels than did patients with early breast cancer (177.9 micrograms/dl vs. 130.4 micrograms/dl) (P less than 0.001). The mean serum zinc levels were lowered only in patients with advanced breast cancer as compared with controls (88.6 micrograms/dl vs. 115.1 micrograms/dl) (P less than 0.001). Serum zinc levels were not decreased in patients with early breast cancer and benign breast diseases. The Cu/Zn ratio was increased in breast cancer patients (1.91 vs. 0.86) (P less than 0.001) but not in patients with benign breast diseases. The precise mechanisms responsible for the alterations in trace element levels in breast cancer patients are still unclear and require further evaluation. However, the serum copper levels and the Cu/Zn ratio may be used as biochemical markers in these patients.     

Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder

INTRODUCTION: The exact role of copper and zinc in the etiology of carcinoma of the gallbladder is unclear. Some studies suggest the Cu/Zn ratio is a good indicator of the extent and prognosis in carcinoma of the gastrointestinal tract. The aim of the present study is to estimate the micronutrient profile and Cu/Zn ratio in the serum, tissues, and bile of patients with benign and malignant gallbladder diseases. METHODS: The present study was carried out in 60 patients comprising 30 each of carcinoma of the gallbladder and cholelithiasis, and 30 age and sex matched controls. Copper and zinc levels were estimated in blood, bile, and tissue using a Perkin Elmer Model 2380 Atomic absorption Spectrophotometer. RESULTS: The mean serum zinc levels were significantly lower in patients with carcinoma of the gallbladder than in patients with cholelithiasis and in healthy controls (P < 0.001). The mean serum copper levels were significantly higher in patients with carcinoma of the gallbladder as compared to patients with cholelithiasis and healthy controls (P < 0.001). Biliary and tissue zinc levels were significantly lower in patients with carcinoma of the gallbladder than in patients with cholelithiasis. Biliary and tissue copper levels were higher in patients with carcinoma of the gallbladder than in patients with cholelithiasis. The serum Cu/Zn ratio showed a gradual and significant increase from 1.11 in healthy controls to 1.35 in patients with cholelithiasis and 2.12 in patients with carcinoma of the gallbladder. The biliary and tissue Cu/Zn ratios were also significantly increased in patients with carcinoma of the gallbladder than in patients with cholelithiasis (P < 0.001). CONCLUSIONS: Our data support an association between lower zinc levels and consequently an increased Cu/Zn ratio and carcinoma of the gallbladder. Whether zinc supplementation has a protective effect in preventing carcinoma of the gallbladder needs to be studied further.     

Serum copper and the copper:zinc ratio in patients with gastric cancer

Serum copper levels, serum zinc levels, and serum Cu:Zn ratios were evaluated in 100 patients with gastric cancer. The following conclusions were drawn from the results: Serum copper levels and the serum Cu:Zn ratio were elevated, while serum zinc levels were decreased, reflecting the progress of the disease. Since serum zinc levels varied more remarkably, it was suggested that this value was more useful than serum copper levels as an indicator of tumor activity. Serum copper and zinc levels were independent of the presence of liver metastasis and of the histological types. It was shown that the serum copper levels correlated (significantly) to the survival time (p less than 0.005).